中文名稱(chēng):ITGB3BP抗體 | 英文名稱(chēng):Rabbit Polyclonal ITGB3BP Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 1707 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類(lèi)別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無(wú) | 靶點(diǎn): ITGB3BP |
WB | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IF | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IHC | 1/50-1/200 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢(xún) | Human,Mouse,Rat |
FCM | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
Aliases | CENPR, NRIF3, TAP20, CENP-R, HSU37139 |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Fusion protein of human ITGB3BP |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P00465(ITGB3BP Antibody) at dilution 1/50. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human brain tissue using P00465(ITGB3BP Antibody) at dilution 1/50. (Original magnification: ×200)
以下是3-4條關(guān)于 **ITGB3BP抗體** 的模擬參考文獻(xiàn)(示例為假設(shè)性文獻(xiàn),僅供參考格式和內(nèi)容方向):
---
1. **文獻(xiàn)名稱(chēng)**: *"ITGB3BP promotes tumor angiogenesis and metastasis via integrin β3 signaling"*
**作者**: Zhang, Y., et al. (2020)
**摘要**: 本研究通過(guò)抗ITGB3BP抗體的阻斷實(shí)驗(yàn),發(fā)現(xiàn)ITGB3BP通過(guò)結(jié)合整合素β3增強(qiáng)腫瘤細(xì)胞的黏附和遷移能力,并激活下游FAK/PI3K通路,促進(jìn)血管生成和癌癥轉(zhuǎn)移。
2. **文獻(xiàn)名稱(chēng)**: *"Autoantibodies against ITGB3BP in systemic lupus erythematosus: diagnostic and pathogenic implications"*
**作者**: Lee, S., & Kim, H. (2019)
**摘要**: 首次報(bào)道系統(tǒng)性紅斑狼瘡(SLE)患者血清中存在抗ITGB3BP自身抗體,提示其可能通過(guò)干擾細(xì)胞外基質(zhì)相互作用參與自身免疫反應(yīng),并可能作為SLE的新型生物標(biāo)志物。
3. **文獻(xiàn)名稱(chēng)**: *"ITGB3BP regulates NF-κB activation through interaction with TRAF2 in inflammatory responses"*
**作者**: Wang, X., et al. (2021)
**摘要**: 利用ITGB3BP特異性抗體進(jìn)行免疫共沉淀實(shí)驗(yàn),證明ITGB3BP通過(guò)與TRAF2蛋白結(jié)合調(diào)控NF-κB信號(hào)通路,影響巨噬細(xì)胞的炎癥因子分泌。
4. **文獻(xiàn)名稱(chēng)**: *"Development of a high-affinity monoclonal antibody for ITGB3BP and its application in ovarian cancer diagnostics"*
**作者**: Gupta, R., et al. (2018)
**摘要**: 開(kāi)發(fā)了一種新型抗ITGB3BP單克隆抗體,驗(yàn)證其在卵巢癌組織中的高表達(dá),并證明其可用于臨床樣本的免疫組化檢測(cè),與患者預(yù)后不良相關(guān)。
---
**注**:以上文獻(xiàn)為模擬示例,實(shí)際研究請(qǐng)通過(guò)學(xué)術(shù)數(shù)據(jù)庫(kù)(如PubMed、Web of Science)檢索真實(shí)文獻(xiàn)。
ITGB3BP (Integrin Beta 3 Binding Protein), also known as TAP20 or NRIF3. is a multifunctional protein involved in cell adhesion, signaling, and transcriptional regulation. It interacts with integrin β3 subunits, modulating integrin-mediated processes like cell migration, proliferation, and survival. Structurally, it contains an N-terminal nuclear localization signal, a central coiled-coil domain, and a C-terminal integrin-binding region, enabling its dual roles in both cytoplasmic/nuclear compartments.
ITGB3BP regulates transcriptional activity by interacting with nuclear receptors (e.g., thyroid hormone receptor) and transcription factors, influencing pathways such as NF-κB and MAPK. It also participates in DNA damage response and stress signaling. Dysregulation of ITGB3BP is linked to cancer progression, cardiovascular diseases, and immune disorders, highlighting its potential as a therapeutic target.
Antibodies targeting ITGB3BP are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate its role in cellular processes and disease models. These antibodies are typically validated for specificity using knockout controls or siRNA knockdown. Commercial ITGB3BP antibodies are often raised against recombinant protein fragments or synthetic peptides corresponding to conserved regions. Researchers utilize them to explore ITGB3BP's involvement in tumor metastasis, angiogenesis, and drug resistance, providing insights into its clinical relevance.
成立日期 | 2024-06-24 (2年) | 注冊(cè)資本 | 50萬(wàn)(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1950 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-08-01 | |
詢(xún)價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1800 |
VIP1年
|
費(fèi)雪(杭州)醫(yī)學(xué)研究有限公司
|
2025-07-28 |